Provided by Tiger Trade Technology Pte. Ltd.

Glaukos

184.89
0.0000
Post-market: 182.00-2.8900-1.56%19:30 EDT
Volume:440.10K
Turnover:81.72M
Market Cap:10.91B
PE:-56.97
High:187.60
Open:185.00
Low:183.68
Close:184.89
52wk High:191.62
52wk Low:73.16
Shares:58.98M
Float Shares:56.44M
Volume Ratio:0.65
T/O Rate:0.78%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2456
EPS(LYR):-3.2819
ROE:-25.98%
ROA:-5.18%
PB:15.98
PE(LYR):-56.34

Loading ...

Company Profile

Company Name:
Glaukos
Exchange:
NYSE
Establishment Date:
1998
Employees:
1094
Office Location:
One Glaukos Way,Aliso Viejo,California,United States
Zip Code:
92656
Fax:
949 367 9984
Introduction:
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Directors

Name
Position
Thomas W. Burns
Chairman, Chief Executive Officer and Director
Aimee S. Weisner
Independent Director
David F. Hoffmeister
Independent Director
Denice M. Torres
Independent Director
Gilbert H. Kliman
Independent Director
Leana S. Wen
Independent Director
Marc A. Stapley
Independent Director
Mark J. Foley
Independent Director

Shareholders

Name
Position
Thomas W. Burns
Chairman, Chief Executive Officer and Director
Joseph E. Gilliam
Chief Operating Officer and President
Alex R. Thurman
Chief Financial Officer and Senior Vice President
Tomas Navratil
Chief Development Officer